Systematic literature review for the association of biomarkers with efficacy of anti-PD-1 inhibitors in advanced melanoma.
Loading...
Embargo End Date
ICR Authors
Authors
Scherrer, E
Rau, R
Lorenzi, M
Shui, I
Townson, S
Larkin, J
Rau, R
Lorenzi, M
Shui, I
Townson, S
Larkin, J
Document Type
Journal Article
Date
2021-03-30
Date Accepted
2021-03-12
Abstract
Aim: Summarize the literature assessing biomarkers in predicting efficacy of anti-PD-1 therapy for patients with high-risk unresectable or metastatic melanoma. Materials & methods: Relevant studies were identified via a systematic literature review. Results: About 334 unique biomarkers or biomarker combinations were identified from 121 citations. Neutrophil-to-lymphocyte ratio was the most frequently studied biomarker, followed by C-reactive protein. Fifty-nine biomarkers were significantly associated with overall survival (OS), 51 with progression-free survival (PFS) and 44 with response. Twenty biomarkers were associated with both OS and PFS; two were associated with OS, PFS and response (MHC-II and tumor mutational burden). Conclusion: Numerous biomarkers could potentially predict the efficacy of anti-PD-1-based therapy for melanoma patients. However, confirmatory studies are needed as well as determination of implications for clinical decision-making.
Citation
Future Oncology, 2021, 17 (20), pp. 2683 - 2692
Source Title
Future Oncology
Publisher
TAYLOR & FRANCIS LTD
ISSN
1479-6694
eISSN
1744-8301
1744-8301
1744-8301